Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Battista, Marco Johannes; Anic, Katharina; Linz, Valerie et al.
G8 score as an independent prognostic factor for patients with endometrial cancer-results of a retrospective single-institution observational cohort studyZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE. Bd. 56. 2023 S. S2-S2
Zeyn, Yanira; Hausmann, Kristin; Halilovic, Melisa et al.
Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3LEUKEMIA. 2023
Jung, Dennis; Almstedt, Katrin; Battista, Marco J. et al.
Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a reviewJOURNAL OF OVARIAN RESEARCH. Bd. 16. H. 1. 2023
Schmidt, M
Immunonkologische Entwicklungen beim MammakarzinomFrauenarzt. Bd. 64. H. 4. 2023 S. 220-224
Almstedt, K; Schmidt, M
In welchen Situationen helfen Genexpressionsanalysen bei der Therapieentscheidung beim frühen Mammakarzinom?gyn - praktische Gynäkologie. Bd. 28. 2023 S. 6-12
Lueck, Hans-Joachim; Schmidt, Marcus; Hesse, Tobias et al.
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort StudyONCOLOGIST. 2023
Battista, Marco Johannes; Anic, Katharina; Schmidt, Mona et al.
Influence of Frailty, preoperative Anemia and perioperative Transfusion Management on Survival of elderly Patients with gynecologic MalignanciesZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE. Bd. 56. 2023 S. S4-S4
Keller, Magdalena; Rohlf, Katharina; Glotzbach, Annika et al.
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growthJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. Bd. 42. H. 1. 2023
Bartsch, Rupert; Harbeck, Nadia; Wrobel, Denise et al.
Interim analysis (n=200) from ELEANOR: a multinational, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routineCANCER RESEARCH. Bd. 83. H. 5. 2023
Bartsch, R.; Harbeck, N.; Wrobel, D. et al.
Interim analysis (n=200) of ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib in the clinical routineONCOLOGY RESEARCH AND TREATMENT. Bd. 46. 2023 S. 170-171